TAK
TAK
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
20
$14.25M
Total Volume
$14.25M
26 transactions
Net Activity
$14.25M
Net selling
Sentiment Rating
Heavy DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Plump Andrew Stewart
Pres, R, D
$5.34M total
Platford Giles Richard
Pres, IBU
$1.69M total
Kim Julie So-Young
Pres, CEO
$1.52M total
Duprey Lauren Rusckowski
Chief Transformation Officer
$1.45M total
Greenway Nicola Deidre Petal
CHRO
$957K total
Quick Actions
TAK has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%. TAK ranks #324 in insider activity out of 569 tracked companies in its industry.
Over the last 90 days, corporate insiders at TAK (TAK) engaged in a total of 26 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 20 were sales. The total volume of insider trading reached $14.25M.
The net insider activity for TAK shows a net selling bias of $14.25M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Plump Andrew Stewart (Pres, R, D), who traded 165.4K shares valued at $2.83M on Aug 10, 2026.
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History
Takeda Pharmaceutical Company Stock Price Forecast. Should You Buy TAK?
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history
Takeda Pharmaceutical (NYSE:TAK) Stock Forecast & Analyst Predictions
TAK - Takeda Pharmaceutical Co ADR Stock Price and Quote
Takeda Pharmaceutical Co. (TAK) Stock Price Prediction for 2026, 2030-2040
Related News & Analyst Reports
Read original insights and educational research covering TAK and the Unknown sector.
Tracking Insider Activity in Biotech: High Stakes and Hidden Signals
Biotech insiders possess unique asymmetric information, clinical results, FDA feedback, partnership negotiations. This guide explains how to track Form 4 activity at pre-commercial biotechs, what position sizes matter, and how to avoid false signals near data events.
Deciphering Option Exercises (Code M) vs. Open Market Purchases (Code P)
Transaction code M (option exercise) is often mistaken for bullish conviction, but it usually means nothing. Learn why Code P open-market purchases are the only Form 4 entries that signal genuine insider belief.
Safe Trading Practices: How to Use Insider Data Responsibly and Legally
A comprehensive guide to understanding the legal boundaries of using publicly disclosed insider trading data, best practices for avoiding common mistakes, risk management principles, and how to integrate SEC filings into a disciplined, compliant investment process.
FAQs About TAK Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for TAK.